Drug Safety Alerts from PvPI-Pharmacovigilance System for India

Drug Safety Alerts from PvPI-Pharmacovigilance System for India

PvPI-Pharmacovigilance Programme for India is a national drug safety monitoring center for India maintained by Indian Pharmacopoeia Commission (IPC) located at Ghaziabad. As part of routine analysis of individual case safety reports (reports of adverse drug event/reactions from a patient) originated from India, PvPI has identified and released two new drug safety alerts for the

Health Canada Drug Safety Updates_June 2020

Drug Safety Updates from Health Canada-June 2020

Health Canada has published new drug safety information to raise awareness to health care professionals and public about the below safety concern which recently made safety labelling changes for the product monograph. –Health Product Info Watch –June 2020. The safety topics discussed below in brief. Pulmonary edema risk with amlodipine Risks of artery dissection and

Drug Safety Alerts from Malaysian Health Authority-June 2020

Drug Safety Alerts from Malaysian Health Authority (NPRA)-June 2020

The Malaysian Health Authority-National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia released the following new drug safety alerts during the month of June. Restriction of domperidone use in pediatric patients less than 12 years of age Risk of oculogyric crisis associated with metoclopramide use (a reminder)   Restriction of domperidone use in pediatric patients

Drug Safety Alerts from New Zealand Health Authority

Drug Safety Alerts from New Zealand Health Authority-MedSafe

MedSafe- Health Authority of New Zealand government has released the below drug safety information in their latest issue-June-2020 to update public-(health care professionals & consumers) about the safe use of medicines.   Tramadol use Contradicted in children & elder patients (<75 y) Oral cleft defects associated with ondansetron   Tramadol use Contradicted in children &

Drug Safety Updates from European medicines agency (EMA)-June 2020

European medicines agency has released a new Issue (135-June-2020) for medicine updates. The drug safety updates from this issue were discussed below in brief. Fatal Drug Interactions between fluoropyrimidines and brivudine Risk of breast cancer with hormone replacement therapy Potential medication errors with Leuprorelin depot medicines   Fatal Drug Interactions between fluoropyrimidines and brivudine European

Metformin Hydrochloride Extended-Release (ER) Tablets: Another voluntary recall

On 11-Jun-2020, a nationwide recall of one lot of Metformin Hydrochloride ER Tablets USP, 500 mg [Lot Number: G901203] issued by Lupin Pharmaceuticals, Inc. due to the detection of N-Nitrosodimethylamine (NDMA). Metformin Hydrochloride is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus. NDMA

Drug Safety Alert From IPC-PvPI

A new drug safety alert (Hydroxychloroquine-Moth Ulceration) released by the Pharmacovigilance Programme of India (PvPI) from Indian Pharmacopoeia commission (IPC) Mouth Ulceration associated with Hydroxychloroquine use Hydroxychloroquine is an antimalarial class of drug which is used in the treatment and prevention of acute attacks of malaria. It also used to treat discoid or systemic lupus

Drug Safety Updates from Health Canada-June 2020

Drug Safety Alert from Health Canada

Health Canada has released a new drug safety information/alert to raise awareness to health care professionals and public about the below safety concern which recently made safety labelling changes for the product monograph. –Health Product Info Watch – May 2020. The safety concern discussed below in brief. Hypofibrinogenaemia associated with Tigecycline use: Tigecycline is a

Drug safety updates from Ireland health authority (HPRA)-May 2020

Below Safety Updates for medicinal products were released for the month of May-2020 by Ireland Health Authority-Health Products Regulatory Agency (HPRA)   A confirmed “Negative Benefit-Risk Profile” for Picato (ingenol mebutate) Risk of abnormal and aggressive behaviors with Levetiracetam use Restricted use of Cyproterone acetate due to risk of meningioma Restricted use of thyroid drugs

Presence of Nitrosamines (N-Nitrosodimethylamine) in Metformin Extended Release formulations

Metformin is a prescription drug and a first line medication used to control high blood sugar in patients with type 2 diabetes. N-Nitrosodimethylamine is a probable human carcinogen which is not harmful when present within the permitted limits. Exposure to some level of nitrosamines is quite common, as these nitrosamines presence are common in water

error: Content is protected !!